<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COVID-19: Issues related to liver disease in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COVID-19: Issues related to liver disease in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">COVID-19: Issues related to liver disease in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Oren Fix, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">K Rajender Reddy, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith D Lindor, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H350994922"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>At the end of 2019, SARS-CoV-2, a novel coronavirus, was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China. Coronavirus disease 2019 (COVID-19) primarily manifests as a lung infection with symptoms ranging from those of a mild upper respiratory infection to severe pneumonia, acute respiratory distress syndrome (ARDS), and death. Medical professionals, including gastroenterology and hepatology clinicians, are tasked with adjusting their practice to curtail the spread of COVID-19, while providing care to their patients.</p><p>This topic will discuss COVID-19-related issues for patients with acute or chronic liver disease. As understanding of COVID-19 continues to evolve, the approach to diagnosis and management may require modification as well. </p><p>Other important aspects of COVID-19 infection are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting"</a> and  <a class="medical medical_review" href="/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127965.html" rel="external">"COVID-19: Issues related to gastrointestinal disease in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1206603294"><span class="h1">LIVER-RELATED RISK FACTORS AND OUTCOMES</span></p><p class="headingAnchor" id="H86818982"><span class="h2">Risk of acquiring infection</span><span class="headingEndMark"> — </span>Whether patients with chronic liver disease are more susceptible to COVID-19 is uncertain. Chronic liver disease in the absence of immunosuppressive therapy is not known to be associated with an increased risk of acquiring COVID-19 [<a href="#rid1">1</a>]. However, the liver may be susceptible to SARS-CoV-2 virus because of angiotensin-converting enzyme 2 (ACE2) receptors in the biliary and liver epithelial cells [<a href="#rid2">2</a>]. SARS-CoV-2 virus binds to the ACE2 receptor to gain entry and damage the target organ [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H1621874351"><span class="h2">Risk of severe COVID-19 and mortality</span><span class="headingEndMark"> — </span>Patients with chronic liver disease or who are immunocompromised may be at higher risk for severe illness from COVID-19 [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with chronic liver disease of any etiology</strong> – Data have suggested that pre-existing liver disease was associated with worse outcomes in patients with COVID-19 [<a href="#rid5">5-14</a>]. In a study of 2780 patients with COVID-19 (including 250 patients with chronic liver disease), patients with chronic liver disease had higher rates of mortality as compared with those without liver disease (12 versus 4 percent; risk ratio [RR] 2.8, 95% CI 1.9-4.0) [<a href="#rid5">5</a>]. Among patients with chronic liver disease, nonalcoholic liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) were the most common etiologies. In subgroup analyses, patients with cirrhosis had a higher risk of mortality compared with no liver disease (RR 4.6, 95% CI 2.6-8.3). The mortality risk was independent of age, race, nicotine use, body mass index, hypertension, and diabetes.</p><p></p><p class="bulletIndent1">The severity of underlying liver disease has also been associated with an increased risk of mortality in patients with COVID-19 [<a href="#rid6">6,12</a>]. In a large database study of patients with chronic liver disease and COVID-19, cirrhosis was associated with higher risk of mortality compared with no cirrhosis, after adjusting for race, liver disease etiology, comorbidities and geographic region (30-day mortality rates: 8.9 versus 1.7 percent; adjusted hazard ratio [aHR] 3.31, 95% CI 2.91-3.77) [<a href="#rid12">12</a>]. In an earlier cohort study that included 152 patients with COVID-19 and chronic liver disease (including 103 patients with cirrhosis) from two international reporting registries, the mortality rate was 40 percent [<a href="#rid6">6</a>]. Deaths occurred in 12 percent of patients with chronic liver disease without cirrhosis. Among patients with Child-Pugh (CP) class A cirrhosis, CP class B cirrhosis, and CP class C cirrhosis, mortality rates were 24, 43, and 63 percent, respectively. CP class B or C cirrhosis were independent predictors of mortality (odds ratio [OR] 4.90, 95% CI 1.16-20.61 and OR 28.07, 95% CI 4.42-178.46, respectively). Mortality in patients with cirrhosis was most often attributed to pulmonary disease (79 percent), while liver-related causes were noted in 12 percent of patients. (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Predictive models'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on immunosuppressive therapy</strong> – Patients on maintenance immunosuppression (eg, liver transplant recipients) are characterized by the CDC as a population that is at risk for severe COVID-19 and its complications (eg, pneumonia) [<a href="#rid4">4</a>]. However, it is unclear if transplant recipients are at higher risk for severe COVID-19 than nontransplant patients. Several studies have reported high mortality rates in solid organ transplant recipients with COVID-19 [<a href="#rid15">15-17</a>], while other studies have suggested that transplantation was not a risk factor for mortality [<a href="#rid18">18-21</a>]. In a cohort study including 151 adult liver transplant recipients and 627 nontransplant patients with COVID-19, liver transplantation was not associated with an increased risk of death as compared with the nontransplant cohort (absolute risk difference 1.4 percent, 95% CI -7.7-10.4) [<a href="#rid18">18</a>]. For liver transplant recipients with COVID-19, risk factors for mortality included increased age (OR 1.06, 95% CI 1.01-1.11), presence of non-liver cancer (OR 18.30, 95% 1.96-170.75) and higher baseline serum creatinine (OR 1.57, 95% 1.05-2.36 per 1 mg/dL increase). Risk factors for mortality from COVID-19 in the general population are discussed separately. (See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Severity of symptomatic infection'</a>.)</p><p></p><p class="bulletIndent1">The effect of immunosuppressive medications on the systemic inflammatory response and acute respiratory distress syndrome (ARDS) is not well understood [<a href="#rid22">22</a>]. However, an overly intense inflammatory host immune response might contribute to disease severity, while it is also possible that low dose immunosuppression may be beneficial in patients with COVID-19 [<a href="#rid23">23</a>]. For example, immunosuppression in transplant recipients was not linked to worse outcomes during the severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) outbreaks [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Adjusting immunosuppression'</a> and <a class="local">'Liver transplantation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with a disease flare</strong> – Whether patients with a flare of chronic liver disease such as hepatitis B virus (HBV) infection or autoimmune hepatitis (AIH) are at higher risk of severe illness from COVID-19 is uncertain. Indirect evidence from an epidemiologic study of patients with SARS suggested that HBV infection was a risk factor for progression to ARDS [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/3027.html" rel="external">"Severe acute respiratory syndrome (SARS)", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors that have not been associated with increased risk</strong> – Antiviral therapy for patients with HBV or hepatitis C virus (HCV) infection has not been associated with increased risk for severe COVID-19. (See <a class="local">'Chronic viral hepatitis'</a> below.) </p><p></p><p class="headingAnchor" id="H1012725666"><span class="h2">Risk of prolonged viral shedding</span><span class="headingEndMark"> — </span>Liver transplant recipients and other immunosuppressed patients who have COVID-19 may have a longer duration of viral shedding than nonimmunosuppressed patients. Thus, strategies for isolation and for testing for clearance may require modification to reduce the risk of spreading infection to others. (See  <a class="medical medical_review" href="/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.) </p><p class="headingAnchor" id="H823243946"><span class="h1">LIVER-RELATED CLINICAL FEATURES</span></p><p class="headingAnchor" id="H41648163"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Patients with or without pre-existing liver disease may present with elevated aminotransferases in the setting of COVID-19 [<a href="#rid5">5,26,27</a>]. Elevated aminotransferase levels have been reported in 14 to 58 percent of hospitalized patients with COVID-19 [<a href="#rid1">1,23,28-36</a>]. The range of aspartate transaminase (AST) and alanine transaminase (ALT) elevations is usually mild (ie, &lt;5 times the upper limit of normal); however, higher aminotransferase levels and severe acute hepatitis have also been reported [<a href="#rid29">29,32,37-41</a>]. The pattern of elevation is often AST greater than ALT, and this pattern has been associated with disease severity [<a href="#rid23">23,33</a>]. AST and ALT are more commonly elevated than bilirubin or alkaline phosphatase, although the angiotensin-converting enzyme 2 (ACE2) receptor is more frequently expressed on cholangiocytes than hepatocytes [<a href="#rid2">2,34,42</a>]. (See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Laboratory findings'</a>.)</p><p>Low albumin has been associated with severe COVID-19 [<a href="#rid31">31,34,43-45</a>]. However, it is unclear if hypoalbuminemia is a risk factor for severe COVID-19 or if hypoalbuminemia is a result of severe COVID-19.</p><p class="headingAnchor" id="H218477138"><span class="h2">Liver histology</span><span class="headingEndMark"> — </span>Liver histology in patients with COVID-19 is nonspecific, including moderate microvesicular steatosis with mild, mixed lobular and portal activity and focal necrosis [<a href="#rid46">46,47</a>]. In a series of 48 autopsies, pathologic liver findings included focal portal and lobular lymphocytic infiltrates and changes suggestive of hepatic vascular involvement [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H2584175302"><span class="h1">DIAGNOSTIC TESTING</span><span class="headingEndMark"> — </span>Considerations in diagnostic testing include when to test for COVID-19 in patients with elevated liver biochemical tests and how to evaluate liver biochemical tests in patients with COVID-19. </p><p class="headingAnchor" id="H3231638959"><span class="h2">When to test for COVID-19 in patients with hepatitis</span><span class="headingEndMark"> — </span>The diagnosis of COVID-19 is usually suspected in patients with new onset fever and/or respiratory tract symptoms (eg, cough, dyspnea) while other consistent symptoms include myalgias and aberrancy in sense of smell or taste  (<a class="graphic graphic_table graphicRef127890" href="/d/graphic/127890.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Initial presentation'</a>.) </p><p>Some patients with COVID-19 have elevated liver biochemistries and/or acute hepatitis, and we favor COVID-19 testing in the following cases (see <a class="local">'Laboratory findings'</a> above and  <a class="medical medical_review" href="/d/html/128404.html" rel="external">"COVID-19: Diagnosis", section on 'Diagnostic approach'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Hospitalized patients with elevated aminotransferases, even in the absence of respiratory symptoms or fever.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Outpatients with established liver disease who present with any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Elevated aminotransferases at least threefold above baseline values with or without jaundice</p><p class="bulletIndent2"><span class="glyph">•</span>Symptoms such as fatigue, abdominal pain, or anorexia that are suggestive of a disease flare (eg, patients with autoimmune hepatitis [AIH] or hepatitis B virus [HBV] infection)</p><p class="bulletIndent2"><span class="glyph">•</span>Features of decompensated liver disease (eg, hepatic encephalopathy)</p><p></p><p>Data from an international registry have suggested that up to 25 percent of patients with new hepatic decompensation and COVID-19 may have no respiratory symptoms at the time of COVID-19 diagnosis [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3666495516"><span class="h2">Evaluating abnormal liver biochemical tests in patients with COVID-19</span><span class="headingEndMark"> — </span>Although elevated liver biochemistries are commonly seen in hospitalized patients with COVID-19, it should not be assumed that these findings are a manifestation of COVID-19. For such patients, the initial evaluation to determine the etiology of elevated liver biochemistries includes (see  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Review the medication list, including outpatient therapies and new medications given during hospitalization, for drugs associated with drug-induced liver injury. (See  <a class="medical medical_review" href="/d/html/3571.html" rel="external">"Drug-induced liver injury", section on 'Associated drugs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obtain serologies for hepatitis A virus (HAV) infection (immunoglobulin M [IgM] anti-HAV), HBV infection (HBsAg, antibody to HBsAg, anti-HBc) and hepatitis C virus (HCV) infection (anti-HCV antibody).</p><p></p><p class="headingAnchor" id="H1548572167"><span class="h1">MANAGEMENT PRINCIPLES</span></p><p class="headingAnchor" id="H3810953161"><span class="h2">General strategies to reduce risk of infection</span><span class="headingEndMark"> — </span>If community transmission of COVID-19 is present, measures to reduce exposure include (see  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Prevention'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>General preventive measures such as hand hygiene and social distancing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of telemedicine visits for ongoing disease management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decreased frequency of routine laboratory and imaging surveillance when the associated risk is deemed to be low. For example, for patients in a surveillance program for hepatocellular carcinoma (HCC), the slow mean doubling time of HCC provides a rationale for this approach [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/d/html/16348.html" rel="external">"Pathology of malignant liver tumors", section on 'Hepatocellular carcinoma'</a> and  <a class="medical medical_review" href="/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>General strategies for reducing the risk of transmitting infection during gastrointestinal (GI) endoscopy are presented separately. (See  <a class="medical medical_review" href="/d/html/127965.html" rel="external">"COVID-19: Issues related to gastrointestinal disease in adults", section on 'Implications for endoscopy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with stable disease and without known or suspected COVID-19, continue the established medication regimen to avoid a disease flare.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients on glucocorticoids, therapy should not be abruptly discontinued, but should be used at the lowest dose possible to control the underlying disease, regardless of COVID-19 exposure or infection status.</p><p></p><p class="headingAnchor" id="H2128197248"><span class="h2">Cirrhosis</span><span class="headingEndMark"> — </span>Patients with cirrhosis are advised to follow general preventive measures to avoid COVID-19, and these are discussed separately. (See <a class="local">'General strategies to reduce risk of infection'</a> above and  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Prevention'</a>.)</p><p>As hospitals and endoscopy centers resume nonurgent procedures, patients with cirrhosis and recent variceal bleeding and/or endoscopic variceal ligation are prioritized before consideration of patients scheduled for elective procedures (eg, upper endoscopy to screen for esophageal varices). (See  <a class="medical medical_review" href="/d/html/1264.html" rel="external">"Endoscopic variceal ligation"</a> and  <a class="medical medical_review" href="/d/html/127965.html" rel="external">"COVID-19: Issues related to gastrointestinal disease in adults", section on 'Implications for endoscopy'</a>.)</p><p class="headingAnchor" id="H4122627497"><span class="h2">Autoimmune hepatitis</span></p><p class="headingAnchor" id="H259183676"><span class="h3">AIH without COVID-19</span><span class="headingEndMark"> — </span>For patients with autoimmune hepatitis (AIH) on maintenance immunosuppression who do not have COVID-19, we do not discontinue or adjust baseline immunosuppression. Patients with AIH are at risk for relapse when immunosuppression is reduced or discontinued, in addition to the potential challenges for inducing remission in the setting of a disease flare [<a href="#rid50">50</a>].</p><p>Patients without COVID-19 who have a flare of AIH are managed with escalating immunosuppression in a manner similar to the pre-COVID-19 era. For such patients, the risk of not treating a disease flare is likely greater than the risk of immunosuppression. Similarly, for patients with newly diagnosed AIH, immunosuppressive therapy can be initiated [<a href="#rid51">51,52</a>]. (See  <a class="medical medical_review" href="/d/html/3659.html" rel="external">"Management of autoimmune hepatitis"</a>.)</p><p class="headingAnchor" id="H1665587738"><span class="h3">AIH with COVID-19</span><span class="headingEndMark"> — </span>For patients with AIH and COVID-19, our approach is individualized based on the severity of infection, patient comorbidities, severity of liver disease, and the existing medication regimen. The goal of medication adjustment is to reduce immunosuppression during active viral replication to lower the risk of COVID-19-related complications, while balancing the risk of disease flare [<a href="#rid50">50</a>]. The general strategy includes:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with asymptomatic or mild COVID-19 (eg, outpatient status, no complications such as pneumonia), we typically do not adjust baseline immunosuppression. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with moderate to severe COVID-19 (ie, patients with pneumonia, hospitalized patients), we assess the patient's prior history of disease relapse and risk for complications of a flare (eg, patients with cirrhosis may be at higher risk for hepatic decompensation). If the immunosuppressive medication (eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>) is adjusted, the baseline dose may be reduced by 25 to 50 percent. We monitor the patient's symptoms and recheck liver biochemical tests daily for hospitalized patients. For patients who do not require hospitalization, we recheck liver biochemical tests in one to two weeks. If the patient's symptoms and liver biochemistries remain stable, the frequency of monitoring is decreased to every two to four weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with COVID-19-related neutropenia and/or lymphopenia (absolute lymphocyte count &lt;1000 cells/microL for adults); we reduce the dose of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> and monitor laboratory studies (white blood cell count and differential) in one to two weeks.</p><p></p><p>Preliminary data have suggested that patients with AIH and COVID-19 were not at increased risk for severe illness and that pre-emptively reducing immunosuppression was not associated with improved outcomes. In a small case series of 10 patients with AIH on immunosuppression and COVID-19, six patients were hospitalized, including five patients with pneumonia and three requiring noninvasive ventilation [<a href="#rid50">50</a>]. Two patients with active AIH were receiving high-dose glucocorticoid therapy at the time of COVID-19 diagnosis and, for both patients, liver biochemistries improved during the hospital course. Nine patients recovered from COVID-19, while one patient with decompensated cirrhosis died. </p><p>The decision to continue immunosuppressive agents, including glucocorticoids, for patients with COVID-19 has been also informed by indirect data suggesting that low dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> has a role in the management of severe COVID-19. The use of glucocorticoids for treating COVID-19 is discussed separately. (See  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Dexamethasone and other glucocorticoids'</a>.) </p><p class="headingAnchor" id="H324176089"><span class="h2">Chronic viral hepatitis</span><span class="headingEndMark"> — </span>The strategy for patients with chronic viral hepatitis depends on presence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, COVID-19 status, and use of therapies to treat COVID-19. (See  <a class="medical medical_review" href="/d/html/3642.html" rel="external">"Hepatitis B virus: Overview of management"</a> and  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H2083722099"><span class="h3">Patients without COVID-19</span><span class="headingEndMark"> — </span>Antiviral therapies for patients with HBV or HCV infection are not known to pose a greater risk of severe COVID-19, and there are no contraindications to initiating or continuing antiviral therapy in patients without COVID-19 during the pandemic [<a href="#rid53">53</a>]. </p><p class="headingAnchor" id="H1099750537"><span class="h3">Patients with COVID-19</span><span class="headingEndMark"> — </span>For patients with chronic viral hepatitis and COVID-19, antiviral treatment for HBV or HCV infection is not contraindicated. For patients with chronic HBV infection and COVID-19, HBV treatment may be indicated (eg, when initiating immunosuppressive therapy in patients with hepatitis B surface antigen or in those with a hepatitis B flare). </p><p>Reactivation of HBV infection has been observed in patients treated with glucocorticoids and <a class="drug drug_general" data-topicid="10208" href="/d/drug information/10208.html" rel="external">tocilizumab</a>, which have been used for treating COVID-19. Thus, HBV prophylaxis may be indicated when initiating these therapies [<a href="#rid54">54-56</a>]. Estimating the patient's risk of HBV reactivation and specific therapies to prevent HBV reactivation are discussed separately. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H1231192986"><span class="h2">Liver transplantation</span></p><p class="headingAnchor" id="H1500302432"><span class="h3">Pretransplantation considerations</span><span class="headingEndMark"> — </span>To minimize the risk of infection and to conserve resources (eg, intensive care unit [ICU] beds, personal protective equipment), elective transplantation (eg, living donor liver transplantation and nonurgent, deceased-donor liver transplants [DDLT]) has been deferred at transplant centers where the community prevalence of COVID-19 is high and/or resources are limited [<a href="#rid57">57</a>]. </p><p>Screening for COVID-19 in donors and potential recipients is discussed separately. (See  <a class="medical medical_review" href="/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Pretransplantation screening'</a>.)</p><p class="headingAnchor" id="H562377834"><span class="h3">Transplant recipients without COVID-19</span><span class="headingEndMark"> — </span>For liver transplant recipients without COVID-19, maintenance immunosuppression is continued without adjustment. While reducing immunosuppression may promote viral clearance, this strategy may also increase risk of developing acute rejection [<a href="#rid58">58</a>]. </p><p>For patients with acute T cell mediated (cellular) rejection (TCMR) of the liver allograft, the approach to management, including high dose glucocorticoids for patients with moderate to severe rejection, has not been altered [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/4598.html" rel="external">"Liver transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection of the liver allograft"</a>.)</p><p class="headingAnchor" id="H4226459651"><span class="h3">Transplant recipients with COVID-19</span><span class="headingEndMark"> — </span>For liver transplant recipients with COVID-19, adjustments to immunosuppression are individualized based on COVID-19 severity, the specific regimen used, time posttransplant, and the risk of allograft rejection (see  <a class="medical medical_review" href="/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Management'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild COVID-19</strong> – For patients with mild COVID-19 (eg, outpatient care, no complications), we do not routinely adjust immunosuppression. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate to severe COVID-19</strong> – For patients with moderate to severe COVID-19 (eg, inpatient care, complications such as pneumonia), general strategies for managing immunosuppression include [<a href="#rid53">53</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We generally lower the overall level of immunosuppression, particularly antimetabolite dosages (eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>) based on general principles for managing infections in transplant recipients and to decrease the risk of superinfection. However, for patients on glucocorticoids, the glucocorticoid dose is not routinely adjusted based on the presence of COVID-19. (See  <a class="medical medical_review" href="/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with COVID-19 related neutropenia and/or lymphopenia (absolute lymphocyte count &lt;1000 cells/microL for adults), we reduce the dose of <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> and monitor laboratory studies (white blood cell count and differential) in one to two weeks.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients on calcineurin inhibitors, we monitor drug levels one to two times a week or as outlined in transplant center-specific protocols because of the risk of acute kidney injury. (See  <a class="medical medical_review" href="/d/html/127552.html" rel="external">"COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension", section on 'Acute kidney injury'</a>.)</p><p></p><p class="headingAnchor" id="H1295252069"><span class="h1">LIVER-RELATED CHRONIC COMPLICATIONS</span><span class="headingEndMark"> — </span>Cholangiopathy has been reported as a late complication of severe COVID-19, and some patients have developed progressive biliary injury and liver failure [<a href="#rid59">59-63</a>]. In a study of 2047 patients who were hospitalized for COVID-19, 12 patients with severe COVID-19 developed a syndrome of cholangiopathy characterized by cholestasis and biliary tract abnormalities that were similar to those seen in critically ill patients with secondary sclerosing cholangitis [<a href="#rid59">59,64</a>]. The mean time from COVID-19 diagnosis to cholangiopathy was 118 days. Imaging findings included inflammation, beading, stricturing, and dilation of the biliary tree. Five patients (42 percent) were evaluated for liver transplantation because of persistent jaundice, hepatic insufficiency, and/or recurrent cholangitis. One patient underwent liver transplantation. Further studies are needed to understand the pathogenesis and to identify preventive and therapeutic measures for cholangiopathy related to COVID-19. </p><p class="headingAnchor" id="H131908484"><span class="h1">COVID-19 SPECIFIC THERAPY AND THE LIVER</span><span class="headingEndMark"> — </span>Elevated liver biochemistries per se are not a contraindication to using therapy such as <a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">remdesivir</a> or to enrolling patients with COVID-19 in trials for investigational agents. However, some patients (eg, those with alanine aminotransferase ≥5 times the upper limit of normal) may be excluded from a clinical trial based on the magnitude of the enzyme elevations. Elevated liver biochemistries have been commonly observed in clinical trials of remdesivir, but elevations have rarely been greater than 10 times the baseline values and have rarely led to treatment discontinuation [<a href="#rid1">1,65,66</a>]. </p><p><a class="drug drug_general" data-topicid="127259" href="/d/drug information/127259.html" rel="external">Remdesivir</a> is not recommended in patients with an alanine aminotransferase ≥5 times the upper limit of normal and should be discontinued if it rises above this level during treatment or if there are other signs of liver injury. Elevated liver biochemistries below this threshold (&lt;5 times the upper limit of normal) should not be a contraindication to starting remdesivir. (See  <a class="medical medical_review" href="/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Remdesivir'</a>.)</p><p class="headingAnchor" id="H3197183766"><span class="h1">COVID-19 VACCINATION</span><span class="headingEndMark"> — </span>Patients with chronic liver disease should receive the COVID-19 vaccine [<a href="#rid67">67</a>]. Several COVID-19 vaccines are available in the United States  (<a class="graphic graphic_table graphicRef130711" href="/d/graphic/130711.html" rel="external">table 2</a>) [<a href="#rid67">67-69</a>]. These vaccines are safe for patients with chronic liver disease, do not contain live SARS-CoV-2, and cannot replicate, even in immunocompromised individuals.</p><p>Data on the immunogenicity of COVID-19 vaccines in this patient population are accumulating [<a href="#rid70">70-77</a>]. In a study comparing 437 patients with chronic liver disease with 144 healthy individuals, chronic liver disease was associated with lower rates of positive SARS-CoV-2 neutralizing antibodies following COVID-19 vaccination (77 versus 90 percent) [<a href="#rid71">71</a>]. There were no statistically significant differences in positivity rates among patients with noncirrhotic chronic liver disease, compensated cirrhosis or decompensated cirrhosis. These data may lend support for additional vaccine doses in patients with chronic liver disease while further studies will help inform vaccine administration in such patients. </p><p>Guidance regarding administration of COVID-19 vaccines is provided separately. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p>Administration of the COVID-19 vaccine does not require interrupting or delaying therapy for hepatitis B or C virus infection or for other liver diseases (eg, autoimmune hepatitis). When possible, candidates for liver transplantation should be vaccinated prior to transplant to ensure sufficient immune response. In addition, vaccination should be provided for individuals who are being evaluated for live liver donation. Vaccination in solid organ transplant recipients is discussed separately. (See  <a class="medical medical_review" href="/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation"</a>.)</p><p>Observational studies suggest that patients with liver disease who receive COVID-19 vaccination have lower risk of both infection and COVID-19-related mortality [<a href="#rid78">78,79</a>]. In a cohort study including over 20,000 patients with cirrhosis, patients who received mRNA vaccine had lower rates of COVID-19 at 28 days after the first dose compared with unvaccinated patients who were matched for age, sex, race, and severity of liver disease (cumulative incidence of infection [day 28-onward] 0.69 versus 0.87 percent, vaccine efficacy 64.8 percent, 95% CI 10.9-86.1) [<a href="#rid78">78</a>]. In a cohort study including nearly 3500 patients with cirrhosis who developed COVID-19, vaccinated patients had lower risk of COVID-19-related mortality compared with unvaccinated patients who were matched for several variables including age, sex, alcohol-related liver disease, and tobacco use (adjusted HR 0.21, 95% CI 0.10-0.42) [<a href="#rid79">79</a>]. </p><p>Studies accounting for other factors such as racial and ethnic differences in disease prevalence are needed to address knowledge gaps about SARS-CoV-2 vaccination in patients with chronic liver disease [<a href="#rid67">67,80,81</a>].</p><p>The impact of other vaccine-preventable infections (viral hepatitis, pneumococcal disease, and influenza) in patients with chronic liver disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/3891.html" rel="external">"Immunizations for adults with chronic liver disease"</a>.)</p><p class="headingAnchor" id="H116804620"><span class="h1">DISEASE REGISTRIES</span><span class="headingEndMark"> — </span>Data on patients with chronic liver disease who have been infected with SARS-CoV-2 virus are accumulating, and we encourage clinicians to report cases of COVID-19 to these registries:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcovidcirrhosis.web.unc.edu%2F&amp;token=Al3Xfw%2F%2FO%2BI2WcLLag7020N%2BV3KSOo7RF36HbDTGnbFp%2BmRqAxHnBwJqt%2BMyy3ld&amp;TOPIC_ID=128410" target="_blank">SECURE-Liver</a> – SECURE-Cirrhosis is an international registry that collects data for patients with chronic liver disease (ie, cirrhosis, liver transplantation recipients) and COVID-19 [<a href="#rid82">82</a>]. The SECURE-Liver registry is aimed to collect patient data from North America, South America, China, Japan, and Korea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcovid-hep.net%2F&amp;token=GDOHlJesKJxD%2BqMepjAIW7KExCWhIWqsarscyo0%2B3Qc%3D&amp;TOPIC_ID=128410" target="_blank">COVID-Hep</a> – COVID-Hep is an international registry that collects data for patients with chronic liver disease (ie, cirrhosis or liver transplantation recipients) and COVID-19 [<a href="#rid83">83</a>]. The COVID-Hep registry is aimed to collect patient data outside of North America, South America, China, Japan, and Korea.</p><p></p><p class="headingAnchor" id="H2764643280"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/126613.html" rel="external">"Society guideline links: COVID-19 – Index of guideline topics"</a>.)</p><p class="headingAnchor" id="H1525279011"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of acquiring infection </strong>– Whether patients with chronic liver disease are more susceptible to COVID-19 is uncertain. Chronic liver disease in the absence of immunosuppressive therapy is not known to be associated with an increased risk of acquiring COVID-19. However, the liver may be susceptible to SARS-CoV-2 virus because of angiotensin-converting enzyme 2 (ACE2) receptors in the biliary and liver epithelial cells. (See <a class="local">'Risk of acquiring infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver-related clinical features </strong>– Common laboratory findings among patients with COVID-19 include elevated aminotransferase levels, while the range of aspartate transaminase (AST) and alanine transaminase (ALT) elevations is usually mild (ie, &lt;5 times the upper limit of normal). However, higher aminotransferase levels and severe acute hepatitis have also been reported. (See <a class="local">'Liver-related clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic testing </strong>– For hospitalized patients with COVID-19, elevated liver biochemistries are common, but these findings are not always a manifestation of COVID-19. For such patients, the initial evaluation to determine the etiology of elevated liver biochemistries includes (see  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a> and <a class="local">'Diagnostic testing'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Review the medication list, including outpatient therapies and new medications given during hospitalization, for drugs associated with drug-induced liver injury.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obtain serologies for hepatitis A virus infection (HAV; IgM anti-HAV), hepatitis B virus infection (HBV; HBsAg, antibody to HBsAg, anti-HBc) and hepatitis C virus infection (HCV; anti-HCV antibody).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management principles</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with cirrhosis </strong>– Patients with cirrhosis are advised to follow general preventive measures to avoid COVID-19, and these measures are discussed separately. (See <a class="local">'General strategies to reduce risk of infection'</a> above and  <a class="medical medical_review" href="/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Prevention'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Autoimmune hepatitis </strong>– For patients with autoimmune hepatitis (AIH) on maintenance immunosuppression who do not have COVID-19, we do not discontinue or adjust baseline immunosuppression. Patients with AIH are at risk for relapse when immunosuppression is reduced or discontinued, in addition to the potential challenges for inducing remission in the setting of a disease flare. (See <a class="local">'Autoimmune hepatitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Liver transplant recipients </strong>– For liver transplant recipients without COVID-19, maintenance immunosuppression is continued without adjustment. For liver transplant recipients with COVID-19, adjustments to immunosuppression are individualized based on COVID-19 severity, the specific regimen used, time posttransplant, and the risk of allograft rejection. (See <a class="local">'Liver transplantation'</a> above and  <a class="medical medical_review" href="/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Active COVID-19 in solid organ transplant recipients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination </strong>– Patients with chronic liver disease should receive the COVID-19 vaccine. The available data suggest that vaccination is associated with lower risk of developing COVID-19 in patients with cirrhosis. (See <a class="local">'COVID-19 vaccination'</a> above.) </p><p></p><p class="bulletIndent1">Guidance regarding administration of COVID-19 vaccines is provided separately. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020; 5:428.</a></li><li><a class="nounderline abstract_t">Chai X, Hu L, Zhang Y, Han W. ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv 2020.</a></li><li><a class="nounderline abstract_t">Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020; 323:1061.</a></li><li class="breakAll">https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.html#immunocompromised-state (Accessed on November 29, 2020).</li><li><a class="nounderline abstract_t">Singh S, Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study. Gastroenterology 2020; 159:768.</a></li><li><a class="nounderline abstract_t">Moon AM, Webb GJ, Aloman C, et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol 2020; 73:705.</a></li><li><a class="nounderline abstract_t">Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol 2020; 73:451.</a></li><li><a class="nounderline abstract_t">Williamson E, Bhaskaran KJ, Bacon S, et al. OpenSAFELY: Factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. MedRxiv 2020.</a></li><li><a class="nounderline abstract_t">Kim D, Adeniji N, Latt N, et al. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. Clin Gastroenterol Hepatol 2021; 19:1469.</a></li><li><a class="nounderline abstract_t">Iavarone M, D'Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol 2020; 73:1063.</a></li><li><a class="nounderline abstract_t">Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. J Hepatol 2021; 74:567.</a></li><li><a class="nounderline abstract_t">Ge J, Pletcher MJ, Lai JC, N3C Consortium. Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study. Gastroenterology 2021; 161:1487.</a></li><li><a class="nounderline abstract_t">Bajaj JS, Garcia-Tsao G, Biggins SW, et al. Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut 2021; 70:531.</a></li><li><a class="nounderline abstract_t">Ioannou GN, Liang PS, Locke E, et al. Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality. Hepatology 2021; 74:322.</a></li><li><a class="nounderline abstract_t">Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant 2020; 20:1800.</a></li><li><a class="nounderline abstract_t">Bhoori S, Rossi RE, Citterio D, Mazzaferro V. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol 2020; 5:532.</a></li><li><a class="nounderline abstract_t">Webb GJ, Moon AM, Barnes E, et al. Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet Gastroenterol Hepatol 2020; 5:643.</a></li><li><a class="nounderline abstract_t">Webb GJ, Marjot T, Cook JA, et al. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. Lancet Gastroenterol Hepatol 2020; 5:1008.</a></li><li><a class="nounderline abstract_t">Colmenero J, Rodríguez-Perálvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol 2021; 74:148.</a></li><li><a class="nounderline abstract_t">Dhampalwar S, Saigal S, Choudhary N, et al. Outcomes of Coronavirus Disease 2019 in Living Donor Liver Transplant Recipients. Liver Transpl 2020; 26:1665.</a></li><li><a class="nounderline abstract_t">Molnar MZ, Bhalla A, Azhar A, et al. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. Am J Transplant 2020; 20:3061.</a></li><li><a class="nounderline abstract_t">Fishman JA. The Immunocompromised Transplant Recipient and SARS-CoV-2 Infection. J Am Soc Nephrol 2020; 31:1147.</a></li><li><a class="nounderline abstract_t">Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497.</a></li><li><a class="nounderline abstract_t">D'Antiga L. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. Liver Transpl 2020; 26:832.</a></li><li><a class="nounderline abstract_t">Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361:1767.</a></li><li><a class="nounderline abstract_t">Dufour JF, Marjot T, Becchetti C, Tilg H. COVID-19 and liver disease. Gut 2022; 71:2350.</a></li><li><a class="nounderline abstract_t">Luxenburger H, Thimme R. SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease. Gut 2023; 72:1783.</a></li><li><a class="nounderline abstract_t">Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382:1708.</a></li><li><a class="nounderline abstract_t">Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507.</a></li><li><a class="nounderline abstract_t">Fan Z, Chen L, Li J, et al. Clinical Features of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol Hepatol 2020; 18:1561.</a></li><li><a class="nounderline abstract_t">Xu L, Liu J, Lu M, et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020; 40:998.</a></li><li><a class="nounderline abstract_t">Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020; 323:2052.</a></li><li><a class="nounderline abstract_t">Lei F, Liu YM, Zhou F, et al. Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China. Hepatology 2020; 72:389.</a></li><li><a class="nounderline abstract_t">Ponziani FR, Del Zompo F, Nesci A, et al. Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients. Aliment Pharmacol Ther 2020; 52:1060.</a></li><li><a class="nounderline abstract_t">Huang H, Chen S, Li H, et al. The association between markers of liver injury and clinical outcomes in patients with COVID-19 in Wuhan. Aliment Pharmacol Ther 2020; 52:1051.</a></li><li><a class="nounderline abstract_t">Hao SR, Zhang SY, Lian JS, et al. Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study. Am J Gastroenterol 2020; 115:1075.</a></li><li><a class="nounderline abstract_t">Bertolini A, van de Peppel IP, Bodewes FAJA, et al. Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis. Hepatology 2020; 72:1864.</a></li><li class="breakAll">Wander P, Epstein M, Bernstein D. COVID-19 presenting as acute hepatitis, Am J Gastroenterol, published April 2020. https://journals.lww.com/ajg/Documents/COVID19_Bernstein_et_al_AJG_Preproof.pdf (Accessed on June 01, 2020).</li><li><a class="nounderline abstract_t">Wu J, Liu J, Zhao X, et al. Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. Clin Infect Dis 2020; 71:706.</a></li><li><a class="nounderline abstract_t">Wang Z, Yang B, Li Q, et al. Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020; 71:769.</a></li><li><a class="nounderline abstract_t">Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054.</a></li><li><a class="nounderline abstract_t">Cai Q, Huang D, Yu H, et al. COVID-19: Abnormal liver function tests. J Hepatol 2020; 73:566.</a></li><li><a class="nounderline abstract_t">Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) 2020; 133:1032.</a></li><li><a class="nounderline abstract_t">Aziz M, Fatima R, Lee-Smith W, Assaly R. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis. Crit Care 2020; 24:255.</a></li><li><a class="nounderline abstract_t">Kovalic AJ, Huang G, Thuluvath PJ, Satapathy SK. Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis. Hepatology 2021; 73:1521.</a></li><li><a class="nounderline abstract_t">Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8:420.</a></li><li><a class="nounderline abstract_t">Yao XH, Li TY, He ZC, et al. [A pathological report of three COVID-19 cases by minimal invasive autopsies]. Zhonghua Bing Li Xue Za Zhi 2020; 49:411.</a></li><li><a class="nounderline abstract_t">Sonzogni A, Previtali G, Seghezzi M, et al. Liver and COVID 19 infection: A very preliminary lesson learnt from histological post-mortem findings in 48 patients. Preprints 2020.</a></li><li><a class="nounderline abstract_t">Rich NE, John BV, Parikh ND, et al. Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis. Hepatology 2020; 72:1654.</a></li><li><a class="nounderline abstract_t">Gerussi A, Rigamonti C, Elia C, et al. Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients. Hepatol Commun 2020; 4:1257.</a></li><li><a class="nounderline abstract_t">Mack CL, Adams D, Assis DN, et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 2020; 72:671.</a></li><li><a class="nounderline abstract_t">Fix OK, Hameed B, Fontana RJ, et al. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology 2020; 72:287.</a></li><li class="breakAll">http://www.aasld.org/ClinicalInsights (Accessed on June 11, 2020).</li><li><a class="nounderline abstract_t">Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148:215.</a></li><li><a class="nounderline abstract_t">Chen LF, Mo YQ, Jing J, et al. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis 2017; 20:859.</a></li><li><a class="nounderline abstract_t">Ekpanyapong S, Reddy KR. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed? Clin Liver Dis 2020; 24:317.</a></li><li><a class="nounderline abstract_t">Agopian V, Verna E, Goldberg D. Changes in Liver Transplant Center Practice in Response to Coronavirus Disease 2019: Unmasking Dramatic Center-Level Variability. Liver Transpl 2020; 26:1052.</a></li><li class="breakAll">https://www.myast.org/sites/default/files/COVID19%20FAQ%20Tx%20Centers%2003.20.2020-FINAL.pdf (Accessed on June 11, 2020).</li><li><a class="nounderline abstract_t">Faruqui S, Okoli FC, Olsen SK, et al. Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications. Am J Gastroenterol 2021; 116:1414.</a></li><li><a class="nounderline abstract_t">Roth NC, Kim A, Vitkovski T, et al. Post-COVID-19 Cholangiopathy: A Novel Entity. Am J Gastroenterol 2021; 116:1077.</a></li><li><a class="nounderline abstract_t">Durazo FA, Nicholas AA, Mahaffey JJ, et al. Post-Covid-19 Cholangiopathy-A New Indication for Liver Transplantation: A Case Report. Transplant Proc 2021; 53:1132.</a></li><li><a class="nounderline abstract_t">Edwards K, Allison M, Ghuman S. Secondary sclerosing cholangitis in critically ill patients: a rare disease precipitated by severe SARS-CoV-2 infection. BMJ Case Rep 2020; 13.</a></li><li><a class="nounderline abstract_t">Meersseman P, Blondeel J, De Vlieger G, et al. Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients. Intensive Care Med 2021; 47:1037.</a></li><li><a class="nounderline abstract_t">Laurent L, Lemaitre C, Minello A, et al. Cholangiopathy in critically ill patients surviving beyond the intensive care period: a multicentre survey in liver units. Aliment Pharmacol Ther 2017; 46:1070.</a></li><li><a class="nounderline abstract_t">Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med 2020; 383:1827.</a></li><li><a class="nounderline abstract_t">Montastruc F, Thuriot S, Durrieu G. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019. Clin Gastroenterol Hepatol 2020; 18:2835.</a></li><li><a class="nounderline abstract_t">Fix OK, Blumberg EA, Chang KM, et al. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology 2021; 74:1049.</a></li><li class="breakAll">Pfizer and BioNTech. FDA briefing document: Pfizer-BioNTech COVID-19 vaccine. Vaccines and related biological products advisory committee meeting. www.fda.gov/media/144245/download (Accessed on March 02, 2021).</li><li class="breakAll">Moderna. FDA briefing document: Moderna COVID-19 vaccine. Vaccines and related biological products advisory committee meeting. www.fda.gov/media/144434/download (Accessed on March 02, 2021).</li><li><a class="nounderline abstract_t">Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383:2603.</a></li><li><a class="nounderline abstract_t">Ai J, Wang J, Liu D, et al. Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study. Clin Gastroenterol Hepatol 2022; 20:1516.</a></li><li><a class="nounderline abstract_t">Wang J, Hou Z, Liu J, et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study. J Hepatol 2021; 75:439.</a></li><li><a class="nounderline abstract_t">Thuluvath PJ, Robarts P, Chauhan M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J Hepatol 2021; 75:1434.</a></li><li><a class="nounderline abstract_t">Bakasis AD, Bitzogli K, Mouziouras D, et al. Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases. Viruses 2022; 14.</a></li><li><a class="nounderline abstract_t">Willuweit K, Frey A, Passenberg M, et al. Patients with Liver Cirrhosis Show High Immunogenicity upon COVID-19 Vaccination but Develop Premature Deterioration of Antibody Titers. Vaccines (Basel) 2022; 10.</a></li><li><a class="nounderline abstract_t">John BV, Doshi A, Ferreira RD, et al. Comparison of infection-induced and vaccine-induced immunity against COVID-19 in patients with cirrhosis. Hepatology 2023; 77:186.</a></li><li><a class="nounderline abstract_t">Li Z, Hu Y, Zou B. The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 patients with cirrhosis. J Hepatol 2023; 79:e157.</a></li><li><a class="nounderline abstract_t">John BV, Deng Y, Scheinberg A, et al. Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis. JAMA Intern Med 2021; 181:1306.</a></li><li><a class="nounderline abstract_t">John BV, Deng Y, Schwartz KB, et al. Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis. Hepatology 2022; 76:126.</a></li><li><a class="nounderline abstract_t">Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis: A Review. JAMA 2020; 323:1175.</a></li><li><a class="nounderline abstract_t">Forde KA, Tanapanpanit O, Reddy KR. Hepatitis B and C in African Americans: current status and continued challenges. Clin Gastroenterol Hepatol 2014; 12:738.</a></li><li class="breakAll">https://covidcirrhosis.web.unc.edu/ (Accessed on December 08, 2020).</li><li class="breakAll">https://covid-hep.net/ (Accessed on December 08, 2020).</li></ol></div><div id="topicVersionRevision">Topic 128410 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32145190" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Liver injury in COVID-19: management and challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32031570" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32031570" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32376408" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease in the United States: A Multicenter Research Network Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32446714" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32278005" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : OpenSAFELY: Factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32950749" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32526252" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : High rates of 30-day mortality in patients with cirrhosis and COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33035628" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34284037" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32660964" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33219546" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32330343" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32278366" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32339474" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Determining risk factors for mortality in liver transplant patients with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32866433" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32750442" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33021025" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Outcomes of Coronavirus Disease 2019 in Living Donor Liver Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32844546" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32345701" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The Immunocompromised Transplant Recipient and SARS-CoV-2 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31986264" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32196933" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12781535" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35701093" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : COVID-19 and liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37316169" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109013" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical Characteristics of Coronavirus Disease 2019 in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32007143" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283325" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical Features of COVID-19-Related Liver Functional Abnormality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32170806" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Liver injury during highly pathogenic human coronavirus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32320003" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32359177" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32628793" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32697870" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The association between markers of liver injury and clinical outcomes in patients with COVID-19 in Wuhan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32618658" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32702162" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32702162" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Abnormal Liver Function Tests in Patients With COVID-19: Relevance and Potential Pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109279" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32176772" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171076" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32298767" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : COVID-19: Abnormal liver function tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32118640" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32456658" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32692464" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32085846" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pathological findings of COVID-19 associated with acute respiratory distress syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32172546" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : [A pathological report of three COVID-19 cases by minimal invasive autopsies].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Liver and COVID 19 infection: A very preliminary lesson learnt from histological post-mortem findings in 48 patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32017165" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hepatocellular Carcinoma Demonstrates Heterogeneous Growth Patterns in a Multicenter Cohort of Patients With Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32838102" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Coronavirus Disease 2019 in Autoimmune Hepatitis: A Lesson From Immunosuppressed Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31863477" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32298473" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32298473" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25447850" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28160426" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32620274" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32369251" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Changes in Liver Transplant Center Practice in Response to Coronavirus Disease 2019: Unmasking Dramatic Center-Level Variability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32369251" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Changes in Liver Transplant Center Practice in Response to Coronavirus Disease 2019: Unmasking Dramatic Center-Level Variability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33993134" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33464757" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Post-COVID-19 Cholangiopathy: A Novel Entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33846012" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Post-Covid-19 Cholangiopathy-A New Indication for Liver Transplantation: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33168538" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Secondary sclerosing cholangitis in critically ill patients: a rare disease precipitated by severe SARS-CoV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34185115" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29023905" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cholangiopathy in critically ill patients surviving beyond the intensive care period: a multicentre survey in liver units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32459919" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32721580" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33577086" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33577086" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33577086" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301246" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34942370" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33905793" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34454993" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35215801" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35335009" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Patients with Liver Cirrhosis Show High Immunogenicity upon COVID-19 Vaccination but Develop Premature Deterioration of Antibody Titers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35712794" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Comparison of infection-induced and vaccine-induced immunity against COVID-19 in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37400016" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The vaccine-response in patients with cirrhosis after COVID-19 vaccination: A systematic analysis of 168,245 patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34254978" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35023206" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32207804" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Nonalcoholic Steatohepatitis: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23811241" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hepatitis B and C in African Americans: current status and continued challenges.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
